The International Journal of Romanian Society of Endocrinology / Registered in 1938

in ISI Thomson Master Journal List

Acta Endocrinologica(Bucharest) is live in PubMed Central

Year Volume Issue First page
From through

  • General Endocrinology

    Capraru OM, Decaussin-Petrucci M, Joly MO, Borda A, Fanfaret IS, Borson-Chazot F, Selmi-Ruby S

    Expression of Menin in the Human Thyroid Gland

    Acta Endo (Buc) 2017 13(2): 154-160 doi: 10.4183/aeb.2017.154

    Introduction. The expression of menin in the thyroid gland has long been debated. Animal models with targeted inactivation of menin in the thyroid gland have shown that its inactivation might play a role in the progression to a more aggressive type of cancer. Human studies are conflicting, some have identified mutations in the MEN1 gene in a subtype of oncocytic thyroid carcinomas, while others have not identified a higher prevalence of thyroid cancer in MEN1 patients. Objective. To analyze the immunohistochemical expression of menin in different types of thyroid carcinomas. Materials and methods. 48 thyroid tumours (12 papillary thyroid carcinomas (PTC), 6 anaplastic thyroid carcinomas (ATC), 12 poorly differentiated thyroid carcinomas (PDTC), 5 medullary thyroid carcinomas (MTC), 5 oncocytic follicular carcinomas (OC), 3 oncocytic adenomas (OA) and 5 goiters (G)) were tested for nuclear expression of menin using an anti-menin antibody. The expression was considered positive, negative or decreased. Results. The expression of menin was positive, identical to normal tissue, in 39 cases (81.25%). The expression was decreased (n=8) or absent (n=1) in 9 tumours (18.75% - 2 PTC, 5 PDTC, 2 OC) accounting for 42% (5/12) of the PDTC and 40% (2/5) of the OC. Conclusions. Our results show that the expression of menin is generally preserved in human thyroid carcinomas, but it can be decreased or absent in certain types of thyroid cancer. Further molecular studies are needed to evaluate to potential of menin protein in tumorigenesis.
  • Endocrine Care

    Zahan AE, Watt T, Pascanu I, Rasmussen AK, Hegedüs L, Bonnema SJ, Feldt-Rasmussen U, Bjorner JB, Nadasan V, Boila A, Merlan I, Borda A

    The Romanian Version of the Thyroid-Related Patient-Reported Outcomes Thypro and Thypro-39. Translation and Assessment of Reliability and Crosscultural Validity

    Acta Endo (Buc) 2018 14(2): 192-200 doi: 10.4183/aeb.2018.192

    Background. ThyPRO is a recently developed thyroid-specific quality of life (QoL) questionnaire applicable to patients with benign thyroid disorders(BTD). The aim of the present study was to translate ThyPRO and ThyPRO-39 into Romanian, and to evaluate reliability and cross-cultural validity. Methods. Standard methodology for translation and linguistic validation of patient-reported outcomes (PRO) was applied. The questionnaire was completed by 130 patients with benign thyroid diseases seen at Department of Endocrinology in the Emergency County Hospital, Tîrgu Mureș, Romania, between October 2015 and March 2016. Internal reliability of the Romanian version of the ThyPRO (ThyPROro) scales was assessed for multi-item scales using Cronbach’s alpha coefficient. An efficient method for testing cross-cultural validity is analysis of differential item functioning (DIF). Uniform DIF between the Romanian and the original Danish sample was investigated using ordinal logistic regression. The translation process proceeded without difficulties, and any disagreements were revised by one of the developers and the language coordinator. Results. Internal reliability for ThyPRO was satisfactory. Cronbach`s alpha coefficients for the 13 scales ranged from 0.78 to 0.93 for the ThyPROro and 0.78 to 0.87 for the ThyPROro-39. In the 85-item ThyPRO, nine instances of DIF were found. Most were minor, explaining <3% of the variation in scale score, but DIF in positively worded items were larger, with explained variance (R2’s) around 10-15%. Conclusion. The ThyPROro questionnaire is ready for assessment of health-related quality of life in Romanian patients with benign thyroid diseases.
  • Endocrine Care

    Szanto Z, Kun IZ, Borda A, Jung J

    Thyroid cancer in two representative medical centers in Mures County between 1984-2007

    Acta Endo (Buc) 2009 5(2): 199-211 doi: 10.4183/aeb.2009.199

    Aim: to evaluate the epidemiology of thyroid cancer (including their different forms)\r\nin two representative medical centers of Mure? County during 1984-2007 under the impact of\r\npossible regional risk factors: ionized radiation from Chernobyl, mild/ moderate iodine\r\ndeficiency (before 2003) and universal iodization of alimentary salt (from 2004).\r\nMethods: In our retrospective study we analysed the data of 288 patients diagnosed\r\nwith thyroid cancer in Endocrinology Clinic and Institute of Pathology T?rgu Mure? in this\r\nperiod. During 1984-1991 the incidence of thyroid cancer did not change practically, it began\r\nto increase progressively from 1992. This first significant elevation between 1992-1999 was\r\nassigned mainly to the newly appeared papillary thyroid carcinomas. Between 2000-2007 a\r\nsecond ascending wave in thyroid cancer incidence was recorded, with a progressively\r\nincreasing tendency.\r\nResults: The incidence was significantly higher compared to 1992-1999 (p<0.0001,\r\nRR=2.05, 95% CI=1.59 - 2.64). This second increase may be assigned, besides the radiation\r\nexposure, to the extension of diagnostic methods (thyroid ultrasonography from 1998 and\r\nfine-needle aspiration cytology from 2000). While before 1991 there were not found thyroid\r\ncancers in children in our county, during 1991-2006 there were registered 10 cases (most in\r\nthe first period): 7 papillary, 2 follicular and one papillary form associated with insular\r\ncarcinoma.\r\nConclusion: the universal iodine prophylaxis (applied from 2004) might influence the\r\ntype of thyroid cancers, increasing the papillary/follicular carcinoma ratio.
  • General Endocrinology

    Ciortea R, Mihu D, Georgescu CE, Borda MI, Ungur RA, Irsay L, Ciortea V

    Influence of the Association of Melatonin and Estrogens on Bone Turnover Markers in Ovariectomised Rats

    Acta Endo (Buc) 2015 11(4): 425-430 doi: 10.4183/aeb.2015.425

    Introduction. Bone formation takes place through a continuous remodeling process, which involves the resorption of old bone by osteoclasts and the formation of new bone tissue by osteoblasts, melatonin contributing to the hormonal modulation of the action of osteoblasts and osteoclasts. Aim. The aim of this study is to evidence the influence of melatonin administered in combination with estrogen on bone turnover markers in female Wistar rats with bilateral surgical ovariectomy. Material and method. The study was performed on 40 female Wistar rats with a weight of 160-200 g, which underwent bilateral surgical ovariectomy. At 14 days postovariectomy, hormone replacement therapy (estradiol benzoate – E2b – 10 μg/day) and combined estrogen (estradiol benzoate – E2b – 10 μg/day) and melatonin (added to the drinking water in a concentration of 25 μg/mL or 50 μg/mL – ethanol concentration 0.01%) – treatment were initiated over a period of 12 consecutive weeks. Subsequently, venous blood was collected for the determination of serum osteocalcin and C-terminal telopeptide of collagen type I levels. Results. Melatonin administered in combination with estrogen to ovariectomized female rats induces an increase in serum osteoalcin levels (statistically significant differences between all four groups p=0.001) and a decrease in serum C-terminal telopeptide of collagen type I levels (statistically significant differences between group I and the other three groups p=0.005; p=0.001; p=0.001 and between group II and group IV p=0.007). The influence on bone formation and resorption markers depends on the administered melatonin dose and on the post-ovariectomy estradiol level. Conclusions. Melatonin potentiates the effects of estradiol on bone in ovariectomized rats.
  • Case Report

    Dema A, Taban S, Borda A, Lazureanu C, Muresan A, Cornianu M, Lazar E, Herman D, Onet D, Popovici D

    Neuroendocrine Dedifferentiation of a Prostate Adenocarcinoma after Hormonal Treatment - A Case Study

    Acta Endo (Buc) 2011 7(4): 535-544 doi: 10.4183/aeb.2011.535

    Background. The concept of NE differentiation in prostate carcinoma has two major aspects: prostate tumors with\r\nprimary NE differentiation and NE differentiation occurred during hormonal therapy for prostate adenocarcinoma, with\r\nthe extreme case of tumor dedifferentiation into a NE hormone resistant carcinoma.\r\nMaterial and method. The patient, 62 years old, with a history of poorly differentiated prostate adenocarcinoma,\r\nhormonally treated with the decrease and then constant maintenance of serum PSA level to 0.01 ng/mL was admitted in the hospital, 8 years after prostate tumor diagnosis, and 3 years after ceasing of hormone therapy, with multiple bone and liver metastases of unknown primary source.\r\nResults. The serum levels of CgA, NSE, CEA, CA19.9, serotonin were elevated. The histopathological examination\r\nof the needle biopsy fragment from a liver metastatic lesion revealed small cell neuroendocrine carcinoma. Despite the\r\nprompt chemotherapy, the disease has progressed, with the occurrence of brain metastases and the patient?s death\r\n6 months after detection of the metastatic disease.\r\nConclusions. The present case confirms the diagnostic difficulties in llymetastatic undifferentiated small cells\r\ntumors, and on the other hand, draws attention to the possibility of NE dedifferentiation as a result of hormone\r\ndeprivation in patients with prostate cancer.